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STUDY PROTOCOL Open Access
Comparative efficacy of pharmacological
and non-pharmacological interventions for
the acute treatment of adult outpatients
with anorexia nervosa: study protocol for
the systematic review and network meta-
analysis of individual data
Tracey D. Wade1*, Janet Treasure2, Ulrike Schmidt2, Christopher G. Fairburn3, Susan Byrne4, Stephan Zipfel5
and Andrea Cipriani3
Abstract
Background: Outpatient treatment studies of anorexia nervosa (AN) are notoriously hard to conduct given the
ambivalence of the patient group and high drop-out rates. It is therefore not surprising that previous meta-analyses
of pharmacological and psychological treatments for outpatient treatment of adult AN have proved to be inconclusive.
Network meta-analysis (NMA) has the potential to overcome the limitations of pairwise meta-analysis, as this approach
can compare multiple treatments using both direct comparisons of interventions within randomized controlled trials
(RCTs) and indirect comparisons across trials based on a common comparator. To date there is no published example
of this approach with eating disorders and the current study provides a protocol which will use NMA to advance
knowledge about what outpatient therapy works best for which patients with AN by conducting both direct and
indirect comparisons of different treatments and the moderating variables.
Methods: Searches of electronic data bases will be supplemented with manual searches for published, unpublished
and ongoing RCTs in international registries, and clinical trials registries of regulatory agencies and pharmaceutical
companies. Two reviewers will independently extract the data and where possible we will access individual data in
order to examine moderators of treatment. Two primary outcomes will be selected: changes to body mass index and
changes to global eating disorder psychopathology. The secondary outcome is the total number of patients who, at
12-month post-randomization, attained over the previous 28 day period: (i) BMI > 18.5, and (ii) global eating disorder
psychopathology to within 1 SD of community norms. We will also provide a statistical evaluation of consistency, the
agreement between direct and indirect evidence.
Results: Descriptive statistics across all eligible trials will be provided along with a network diagram, where the size of
the nodes will reflect the amount of evidence accumulated for each treatment. We will use a contribution matrix that
describes the percentage contribution of each direct meta-analysis to the entire body of evidence.
(Continued on next page)
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Discussion: Findings will make a major contribution to the literature by summarising individual data across rapidly
accumulating outpatient trials of AN using state of the art NMA methodology.
Trial registration: PROSPERO registration number: CRD42017064429
Keywords: Network meta-analysis, Anorexia nervosa, Outpatient treatment
Background
Anorexia nervosa (AN) is an eating disorder characterised
by behavioural disturbance related to eating or weight con-
trol practices that leads to a significantly low body weight, a
disturbance in the experience of body shape and/or weight,
and a significant impairment in physical, social, vocational
and psychological functioning. The restricting subtype in-
volves energy restriction, increased energy expenditure,
fasting and other non-purging compensatory behaviours in
the absence of binge eating; the binge-eating/purging type
includes the presence of binge eating or purging behaviours
(or both). The proposed ICD-11 and DSM-5 criteria for
AN are similar, including the weight specification and re-
moval of the requirement of amenorrhoea that was present
in previous systems of diagnosis.
While severe AN is typically treated in an inpatient or
residential environment using multimodal treatment de-
livered by multidisciplinary teams [1], there is consensus
that outpatient psychotherapy is required in addition to
specialist care that includes nutritional rehabilitation
and weight restoration in order to achieve recovery [2].
While there is evidence for the benefit of including par-
ents in outpatient treatments for young people (i.e., <
18 years) [3–5], no specific outpatient psychotherapy has
shown superiority for adults with AN [1]. A meta-analysis
of 57 psychological treatment studies was inconclusive [6],
yielding no salient results supporting a particular therapy
technique, setting or procedure. Additionally, there is no
clarity on the most effective pharmacotherapy for this
disorder. In a meta-analysis of a small number of
pharmacotherapy studies, pooled effect sizes of the dif-
ference between placebo and both antidepressants and
antipsychotics on weight were not significant [7]. Hor-
monal therapy had a significantly larger effect on
weight compared to placebo but heterogeneity was
high, indicating caution with respect to interpretation
of the results.
In part, these inconclusive findings are explained by a
lack of power. Given the high mortality rate associated
with AN, the use of non-active comparator conditions is
rare, and there are relatively small numbers of partici-
pants in any given study due to the ambivalence of this
client group to receive and remain in treatment [8]. This
also means that treatment studies have not been able to
sufficiently address the more complex treatment ap-
proaches seen in routine clinical practice [1], such as
multidisciplinary treatment or adjunctive use of hospital
admission for physical safety.
However the number of studies investigating out-
patient treatment approaches for AN is rapidly increas-
ing. For example, in 2013 there were 40 randomised
controlled trials (RCTs) in progress around the same
amount of trials that had emerged over a 30 year period
between 1981 and 2013 [1]. Given the last meta-analysis
of psychological treatments was conducted in 2011 and
the results of the 40 RCTs have not yet been captured in
systematic reviews, it is now timely to consider another
meta-analysis. In particular, network meta-analysis
(NMA) is an ideal tool to apply to such an area in terms
of advancing knowledge about what works best for
whom as it is a statistical technique that allows both dir-
ect and indirect comparisons to be undertaken, even
when pairs of the treatments have not been compared
directly (head to head) in the same trial [9, 10]. Of the
40 studies mentioned above, only 9 (23%) directly com-
pared different types of therapy (as opposed to studies
which compare medications, or forms of cognitive be-
haviour therapy [CBT] or forms of family therapy).
Traditional meta-analyses would be unable to provide
direct comparisons but NMA can provide point esti-
mates of relative efficacy between all interventions even
though some have never been compared head to head,
as well as an estimate of inconsistency e.g., how well the
entire network fits together. NMA has already been used
successfully in other fields of psychiatry [11].
However, in the field of AN there is heterogeneity in
treatment effects and many factors can have an impact
on the relative treatment. In order to identify the prog-
nostic factors (variables that predict overall response re-
gardless of the treatments) and effect modifiers
(variables that predict differential response to alternative
treatments), the best methodological approach is to
apply meta-regression to the NMA of individual partici-
pant data (IPD-NMA) [12]. It will enable a more power-
ful examination of the influence of both group-level and
individual-level characteristics on the outcomes in the
comparison of three or more alternative treatments [9].
The objective of the proposed systematic review and
NMA is to compare acute phase monotherapy treat-
ments of AN in terms of efficacy and acceptability in
order to better inform clinical practice and mental
health policies at the individual patient level.
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Methods/Design
Criteria for considering studies for this review
Types of studies
Given the challenges inherent in conducting large treat-
ment studies for AN and the need to increase our power
as far as possible, only RCTs (either double-blind, single-
blind or non-blind reported as comparing one active
outpatient condition with another, or with wait list)
offering acute phase treatment of AN will be included.
Acute phase of illness is defined as treatment with par-
ticipants who currently meet criteria for AN; this can be
contrasted to maintenance therapy, where participants
are randomised to therapy arms after weight restoration
[1]. Only monotherapy studies will be included, defined
as treatments that were not primarily used as an aug-
mentation strategy (e.g., to an inpatient or outpatient
treatment, or as maintenance of weight gain after a
lengthy inpatient admission). Given that weight loss is
central to the psychopathology of AN, individuals will be
included if they had to have short inpatient stays for the
purpose of medical stabilisation in order to enable them
to participate in the main curative therapy (either before
therapy commences or during therapy. Across studies,
the use of short-term hospitalisation is commonly incor-
porated into the analyses. For example, the Anorexia
Nervosa Treatment of Outpatients study incorporated
intermittent inpatient treatment of up to 4 weeks in
order to enable a BMI > 15 to be attained as required by
their ethics approval process for outpatient treatment
[13]. In two different comparisons of specialist support-
ive clinical management and the Maudsley Model of An-
orexia Nervosa Treatment for Adults (MANTRA), days
of hospital care were recorded and compared between
the groups [14, 15].
Types of participants
Patients aged 18 years or older, of both sexes, with a pri-
mary diagnosis of AN, will be included. Studies adopting
any standard operationalised diagnostic criteria to define
patients suffering from anorexia nervosa will be included
e.g., DSM-III, DSM-IIIR, DSM-IV, DSM-5 and ICD-10.
Studies using clinical cut-off scores on symptom rating
scales to indicate a potential disorder will not be in-
cluded, and neither will studies that rely on participant
self-report, but where participants self-report past
12 month diagnosis of AN from a doctor, or past
12 month treatment for AN (including hospital admis-
sion), these will be included.
Given that the presence of other psychiatric disorders
are common (e.g., depression and anxiety disorders), and
their status as primary or secondary diagnoses is unclear
until the AN is treated, all concurrent diagnoses will not be
considered as an exclusion criterion, but will be recorded
for examination as a moderating factor. Patients will need
to have completed the intensive form of the treatment to
be included in this NMA but may still be receiving some
type of maintenance support, including medications.
Types of interventions
We are interested in comparing therapeutic modalities
that have the aim of achieving remission during the
acute phase of illness. Definitions of remission typically
include both body mass index (BMI) and eating disorder
psychopathology, as it is not uncommon for treatment
to lead to improvement in one but not both [e.g., 14],
where the patient is still considered to have significant
impairment. The specific modalities to be investigated
include the following: antidepressants, antipsychotics,
hormonal treatment, CBT, behavioural therapy, treat-
ment as usual (TAU), cognitive analytic therapy, focal
psychodynamic psychotherapy (FPT), interpersonal psy-
chotherapy, specialist supportive clinical management
(formerly non-specific supportive clinical management),
ego-oriented individual therapy/adolescent-focused indi-
vidual therapy, body awareness therapy, family-based
treatment/family therapy, MANTRA, cognitive interper-
sonal treatment, cognitive remediation therapy, Lough-
borough Eating disorders Activity therapy, exposure and
response prevention, and psychoanalytic psychotherapy.
Search strategy and study selection
The following electronic databases will be searched: CEN-
TRAL, CINAHL, MEDLINE, MEDLINE In-Process and
PSYCINFO. The electronic searches will be supplemented
with manual searches for published, unpublished and on-
going RCTs in international registries (such as clinical-
trials.gov), and clinical trials registries of regulatory
agencies and pharmaceutical companies (see Appendix for
the full list of resources). It is important to include unpub-
lished data, since publication bias leads to exaggerated ef-
fect sizes and reporting bias can bias NMA-based
estimates of treatments efficacy and modify ranking [16].
Studies will be identified using Keywords anorexia*
(abstract) and treat* (abstract). No data limits or language
restrictions will be applied to any of the searches. The
reference lists of included studies will be searched for add-
itional studies. Where eligible studies are found, supple-
mental data will be requested from the investigators if
needed. We will include all studies, irrespective of their
country of origin, identified in the international databases
listed above and satisfying our eligibility criteria. Two per-
sons will independently select references and abstracts re-
trieved by the search. If both reviewers agree that a trial
does not meet eligibility criteria, it will be excluded. We
will obtain the full text of all remaining articles and use
the same eligibility criteria to determine which, if any, to
exclude at this stage. Any disagreements will be resolved
via discussion with a third member of the review team.
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Outcome measures
Dependent variables
Primary outcomes Clinical trials of AN adopt relatively
homogenous continuous outcomes, commonly including
BMI and global eating disorder psychopathology. The
use of dichotomous cut-offs related to BMI outcome are
complex, given the wide variation across studies for
entry BMI. Therefore, this review will give priority to the
use and analysis of continuous variables. Two primary
outcomes will be selected: (i) changes to BMI and (ii)
changes to global eating disorder psychopathology, mea-
sured by using the end point global score on the Eating
Disorder Examination (EDE; an investigator-based struc-
tured and standardised interview or the self-report ques-
tionnaire [17]). If the EDE was not used, we will
consider other standardised rating scales. This repre-
sents a more relaxed criteria than remission and has
been chosen so that we can identify which therapies may
be more effective for one outcome than another, given
that both do not necessarily improve together over the
course of treatment.
Secondary outcomes Given that outpatient treatment
for AN varies between 5 and 12 months [13, 14], remis-
sion (strict criteria) will be defined as the total number
of patients who, at 12-month post-randomization,
attained over the previous 28 day period: (i) BMI > 18.5,
and (ii) global eating disorder psychopathology or global
assessment of functioning or health-related quality of life
to within 1 SD of community norms. Use of this defin-
ition has shown that patients with AN are indistinguish-
able from healthy controls on several eating disorder
related cognitions [18], and has been used across a num-
ber of treatment studies [13–15, 19].
In order to capture improvement that does not meet
strict criteria for remission, we will also examine the
total number of patients who, at 12-months post-
randomisation, attained over the previous 28 day period:
(i) an increase in 2 BMI points from baseline, and (ii) a
decrease of global eating disorder psychopathology or
global assessment of functioning or health-related qual-
ity of life to within 2 SD of community norms. Two
other secondary outcome measures will be used. The
first is drop-out, which indicated acceptability of the
treatment. The second is the use of hospitalisation after
treatment has been completed over the follow-up period.
Studies that do not report data in a format amenable to
the NMA will be described in the systematic review.
Independent variables
The literature suggests many candidates for effect predic-
tors (variables associated with response regardless of the
treatment) and for effect modifiers (variables associated
with differential response depending on the treatment) in
the treatment of anorexia. We have listed in Table 1 the
possible candidate variables for effect predictors and effect
modifiers based on the literature [20]. The variables will
first be limited by their availability in the included original
studies, but when several variables that measure similar
things are available, the research team will discuss those
we believe are the most important predictors and those
that should be included in the model. We will also exam-
ine this limited set of variables in the meta-regression for
the primary outcomes only.
Data collection and management
Individual participant data including the dependent as
well as independent variables as specified below will be
sought from the principal investigators of all the identi-
fied trials. The veracity of the obtained data will be cross
examined by calculating the summary statistics (num-
bers and percentages, or means and SDs) of the baseline
demographic as well as clinical variables, and comparing
them against the published reports.
Data extraction
Two reviewers will then independently read each article/
study report, extract the data and assess the quality of
the study (see details below). We will design and use a
structured data extraction form to ensure consistency of
information and appraisal for each study. Information
extracted will include study characteristics (such as lead
author, publication year, country and journal), partici-
pant characteristics (such as diagnostic criteria for AN,
Table 1 Candidate variables for effect predictors and effect
modifiers based on the literature
Category of variable Specific variable and expected direction
in terms of predicting better outcome
Life and social history Less child maltreatment
Better social adjustment
Being male
History of present illness Older age of onset
Shorter duration of illness
Less prior treatments
Present illness:
symptomatology
Higher baseline body mass
index
Less frequent binge/purge
behaviours
Lower levels of comorbid
psychopathology
Less days of inpatient hospitalization
for the purpose of medical stabilization
during the treatment trial
Use of adjunctive treatment over the
follow-up period
Higher number of outpatient sessions
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age, sex, setting, baseline BMI, concurrent diagnosis of
another mental disorder, number of days of inpatient
treatment for the purpose of medical stabilisation, num-
ber of outpatient sessions, days of adjunctive treatment
over the follow-up period), intervention details, and out-
come measures. Two review authors will ascertain that
the data are entered correctly into the final dataset.
When published and unpublished studies provide differ-
ent values, we will prioritise the unpublished data.
Continuous outcomes
We will extract means and SD from each study and
enter these into an Excel sheet. In the absence of SD, we
will use the guidelines provided by the Cochrane Hand-
book for Systematic Reviews of Interventions [21] for esti-
mating SD from confidence intervals, standard errors, t
values, P values, F values, and changes from baseline. We
will use comprehensive meta-analysis software (https://
www.meta-analysis.com) to estimate the required statis-
tics. When required statistics are not recorded, the au-
thors will be asked to supply the data. If SD are not
reported and not provided by the authors, the mean value
of known SD will be calculated and borrowed from the
group of included studies. Change in both directions will
be noted i.e., increases and decreases in the two primary
outcome variables, BMI and global eating disorder psy-
chopathology. When mixed method repeated measures or
other appropriate imputation methods are used, we will
prefer these results.
Dichotomous outcomes
We opt for the number of respondents per treatment
arm who meet criteria for remission (both strict and le-
nient criteria). When these numbers are not reported
but baseline mean and endpoint mean and standard de-
viations of the eating disorder rating scales (such as
EDE) are provided, we will calculate the number of
responding patients at 12-month post-randomization
(range 40 to 60 weeks) employing multiple imputation
[22]. Below we also discuss our strategy when means
and/or standard deviations are not reported in the
articles.
Missing outcome data
Using the individual patient data, we will judge comple-
tion as attending 75% of the allotted sessions. Outcomes
of patients that leave the study early are typically im-
puted by the trialists, and it is very rare for an article to
report the outcome separately for fully observed and
imputed data and the summary statistics that we will
collect are bound to refer to both study completers,
moved to a different treatment, and patients who termi-
nated treatment all together. The appropriateness of the
imputation method to account for early dropouts will be
considered in the Risk of Bias assessment. After imputa-
tions at the individual participant level by the original
authors, the outcome might be unknown (and not im-
puted by the original authors) for a very small propor-
tion of study participants. For the dichotomous efficacy
outcome we will assume that participants with an un-
known outcome are non-responders.
Length of trial
Typically across different studies efficacy is assessed at
varying time periods, but all studies typically report on an
observation around 12-months post-randomisation and
this will be our follow up duration of interest. Clinicians
need to know whether (and to what extent) treatments
sustain effects over a period of time. If 12-month (i.e. 52-
week) post-randomisation data are not available, we will
use data as close to this as possible (ranging between 40
and 60 weeks).
Risk of bias assessment
We will assess risk of bias in the included studies using
the tool described in the Cochrane Collaboration Hand-
book as a reference guide [21]. The assessment will be
performed by two independent raters. If the raters dis-
agree, the final rating will be made by consensus with the
involvement (if necessary) of another member of the re-
view group. We will evaluate the risk of bias in the follow-
ing domains: generation of allocation sequence, allocation
concealment, blinding of study personnel and participants,
blinding of outcome assessor, attrition, selective outcome
reporting and other domains. Where inadequate details of
allocation concealment and other characteristics of trials
are provided, the trial authors may be contacted in order
to obtain further information. We will not include studies
where sequence generation was at high risk of bias and
where allocation was clearly not concealed.
Statistical synthesis of study data
We will synthesise data using a one-step IPD meta-
analysis model assuming independent interaction be-
tween treatment effects and covariates, as described by
Donegan et al. (model 2) [23]. We will ‘borrow strength’
across the multiple time points by assuming that the ob-
servations from each patient follow a multivariate nor-
mal distribution, thus accounting for the correlation
between the observations [12]. Then, for study j compar-
ing treatments X and Y, for the observations at the
study’s end point we will assume that:
mijX = uj + αjxij, if patient i received treatment X
mijY ¼ uj þ αjxij þ βDX−βDYð Þ xij−x
 þ δjYX þ μDX−μDY
, if patient i received Y
where X is the (arbitrarily chosen) reference treatment
for study j, δj ~N(0, τ
2) τ2 is the heterogeneity (common
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for all comparisons), xij is a covariate, and the coeffi-
cients β measure the interaction between the relative
treatment effects and the covariate values. The coeffi-
cients αj measure the impact of the covariate on the
endpoint outcome that is irrespective of the treatment
being taken. The model described above pertains to both
continuous and dichotomous outcomes. The latter will
be assumed to follow a Bernoulli distribution, where
mijk(k = X, Y) will correspond to log-odds. We will opt
for IPD data from all included studies; however, if there
are studies for which only aggregated data are available
(AD) we will include those as described in Donegan et
al. [23] by distinguishing within-trial and between-trials
(model 5). If a trial is identified that compares all three
interventions we will substitute the random-effects dis-
tribution of δj for its bivariate distribution. The model
will be fitted in OpenBUGS using vague priors for all lo-
cation parameters (effect sizes and regression coeffi-
cients). For the heterogeneity, we will use a half-normal
prior on the standard deviation. We will use as regres-
sors the select variables from the above list.
We are going to include studies examining both non-
pharmacological and pharmacological interventions for
outpatient treatment of AN in adults. Of the trials of
which we are currently aware [1], there may be no mono-
therapy studies utilising pharmacology for the treatment
of the acute phase of AN (typically medication is used as
an adjunctive therapy), so it may be that no common
comparator exists between non-pharmacological and
pharmacological interventions. In this case we will have
two separate networks: one network of studies which
compare drug X with drug Y or placebo as an adjunctive
therapy (Network 1) and another network of studies com-
paring psychotherapy A with psychotherapy B or TAU
(Network 2) as a monotherapy approach.
Missing data
We will impute missing data in OpenBUGS assuming a
missing at random (MAR) missingness mechanism [24].
Estimation of heterogeneity and inconsistency
We expect that heterogeneity and inconsistency intro-
duced by variability in patient characteristics will be
accounted for by the meta-regression model. Residual het-
erogeneity in the data will be measured by monitoring the
common heterogeneity parameter τ2 and by comparing it
to its empirical distribution [25, 26]. Residual inconsist-
ency will be assessed by estimating the difference w
between direct and indirect estimates in the drug-
psychotherapy-combination loop of evidence. This will be
achieved by adding w in the equation for mijP, for studies
comparing psychotherapy and combination therapy.
Assessment of inconsistency
The strategical and conceptual evaluation of transitivity
(i.e., whether it was equally likely that any patient in the
network could have been given any of the treatments in
the network) will be supplemented with a statistical
evaluation of consistency, the agreement between direct
and indirect evidence. We will employ local as well as
global methods to evaluate consistency [27]. Local
methods detect ‘hot spots’ of inconsistency, evidence
loops that are inconsistent or comparisons for which dir-
ect and indirect evidence disagree. We will employ the
loop-specific approach to evaluate inconsistency within
each loop of evidence, and a method that separates
direct evidence from indirect evidence provided by the
entire network [28]. We will also evaluate consistency in
the entire network by calculating the I2 for network het-
erogeneity, inconsistency, and for both [29, 30]. Inter-
pretation of the statistical inference about inconsistency
will be carried out with caution and possible sources of
inconsistency will be explored even in the absence of
evidence for inconsistency.
GRADE quality assessment of all comparisons in the
network
We will also assess the quality of evidence contributing
to network estimates of the main outcomes with the
GRADE framework, which characterizes the quality of a
body of evidence on the basis of the study limitations,
imprecision, inconsistency, indirectness and publication
bias [27]. The starting point for confidence in each net-
work estimate is high, but will be downgraded according
to the assessments of these five domains.
Dissemination
We will publish findings from this systematic review in a
peer reviewed scientific journal and dataset will be made
freely available. The completed review will be dissemi-
nated electronically, in print and on social media, where
appropriate.
Discussion
Our aim to is examine individual data across all available
outpatient studies of adult AN in order to offer up a
more definitive comparison between different treat-
ments, as well as examining the impact of moderators of
treatments, in order to make specific conclusions about
which therapies may best suit which patients. Recent
eating disorder practice guidelines for Australia and
New Zealand [31] concluded that we are unable to make
any robust and direct comparison between commonly
used psychological treatments for AN, like CBT, inter-
personal psychotherapy, or psychodynamic psychother-
apy, and that interpretation of findings where specific
psychological therapies are compared to other therapies
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is problematic because of methodological problems. The
guidelines also note that currently that CBT and its
many forms is probably the most recommended specific
psychotherapy for AN.
This proposed NMA has the potential to resolve this
impasse, by having greater power to directly compare
therapies to each other, in part due to the emergence of
many new studies since the last meta-analysis was pub-
lished, and in part due to the using the network to com-
pare therapies that have not previously been directly
compared to each other. This will allow us to start to
make some conclusions as to whether the evidence sup-
ports some front runner therapies for adult outpatient
AN. Given the current state of affairs, which seems to
support the idea that a range of different therapies may
have merit [31], the NMA can use individual data to
examine putative moderators of treatment, and provide
a more nuanced suggestions for clinicians, such as which
type of therapy works best for which type of patient.
Appendix: List of research registers that will be
searched
◦ European Clinical Trials Database (EudraCT)
UMIN Clinical Trials Registry (UMIN-CTR)
◦ JapicCTI (http://www.clinicaltrials.jp/user/
cteSearch_e.jsp)
◦ Japan Medical Association Centre for Clinical Trials
(JMACCT)
◦ UK National Research Register [for archived content
only]
◦ WHO International Clinical Trials Registry Platform
(WHO ICTRP) [includes datasets from the following
providers]:
o Australian New Zealand Clinical Trials Registry
(ANZCTR)
o Brazilian Clinical Trials Registry (ReBec)
o Chinese Clinical Trial Registry (ChiCTR)
o Clinical Research Information Service - Republic of
Korea (CRIS)
o Clinical Trials Registry - India CTRI)
o ClinicalTrials.gov
o Cuban Public Registry of Clinical Trials (RPCEC)
o EU Clinical Trials Register (EU-CTR)
o German Clinical Trials Register (GermanCTR)
o ISRCTN
o Iranian Registry of Clinical Trials (IRCT)
o Japan Primary Registries Network (JPRN)
o Netherlands National Trial Register (NTR)
o Pan African Clinical Trial Registry (PACTR)
o Sri Lanka Clinical Trials Registry (SLCTR)
o Thai Clinical Trials Register (TCTR)
For extra sensitivity we will undertake our own searches
in some of the key registers that provide datasets for inclu-
sion in WHO ICTRP. The list of registers is as follows:
 Australian Clinical Trials Registry (ANZCTR)
 clinicaltrials.gov
 ISRCTN
 Netherlands National Trial Register (NTR)
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